MAPT and Alzheimer disease: Indeed, our independent study in the mouse model of AD that along with the mutant human APP and PS1 proteins also expresses mutant human Tau protein, the 3xTg-AD mice70, demonstrated that chronic CP2 treatment reduced pTau levels and improved LTP and energy homeostasis in symptomatic male and female mice.